Use of New Antibiotics in Sweden

Plain-language summary

This observational study examined the use of new antibiotics (such as cefiderocol, ceftazidime-avibactam, and meropenem-vaborbactam) in the treatment of acute infections in Sweden. It enrolled patients treated with one of these antibiotics for an acute infection. This non-phase study has been conducted and is completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Uppsala University

Start date

11/1/2021

Estimated completion

12/30/2023

Countries

Sweden

Related genes

Locations

• Gothenburg, Sweden
• Linköping, Sweden
• Lund, Sweden
• Örebro, Sweden
• Stockholm, Sweden
• Umeå, Sweden
• Uppsala, Sweden

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Treatment with any of the following antibiotics; cefiderocol, ceftazidim-avibactam, ceftolozan-tazobactam, fosfomycin, meropenem-vaborbactam or imipepenem-relebactam against an acute infection.

Exclusion Criteria:

* Ongoing treatment with any of the above mentioned antibiotics for more than seven days at the point of inclusion.